Cargando…

A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer

A multicentre study evaluated the efficacy and safety of darbepoetin alpha administered weekly (QW), every 3 weeks (Q3W), and every 4 weeks (Q4W) to anaemic patients with cancer not concurrently receiving chemotherapy or radiotherapy. The QW portion (n=102) was an open-label, sequential, dose-escala...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, R E, Tchekmedyian, N S, Chan, D, Meza, L A, Northfelt, D W, Patel, R, Austin, M, Colowick, A B, Rossi, G, Glaspy, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741110/ https://www.ncbi.nlm.nih.gov/pubmed/12799626 http://dx.doi.org/10.1038/sj.bjc.6600994

Ejemplares similares

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
por: Glaspy, J A, et al.
Publicado: (2002)

Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer
por: Smith, R E, et al.
Publicado: (2001)

A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy
por: Glaspy, J, et al.
Publicado: (2001)

Darbepoetin, effective treatment of anaemia in paediatric patients with chronic renal failure
por: André, Jean-Luc, et al.
Publicado: (2007)

A proposal of the simple guide regarding the conversion ratio from epoetin to darbepoetin alpha in treating haemodialysis patients with renal anaemia
por: Nakagawa, Tetsuya
Publicado: (2008)

Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia
por: Grossi, Alberto, et al.
Publicado: (2007)

Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations
por: Carrera, Fernando, et al.
Publicado: (2009)

Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma
por: Shannon, A M, et al.
Publicado: (2005)

Extended dosing of darbepoetin alfa in peritoneal dialysis patients
por: Feriani, Mariano, et al.
Publicado: (2011)

Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes
por: Gabrilove, Janice, et al.
Publicado: (2008)

Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia
por: Wauters, Isabelle, et al.
Publicado: (2006)

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
por: Arrieta, Javier, et al.
Publicado: (2014)

Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta‐analysis
por: Park, Sophie, et al.
Publicado: (2016)

Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial
por: Schwartzberg, Lee, et al.
Publicado: (2010)

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
por: Akizawa, Tadao, et al.
Publicado: (2020)

The Use of Darbepoetin to Stimulate Erythropoiesis in the Treatment of Anemia of Chronic Kidney Disease in Dogs
por: Fiocchi, E.H., et al.
Publicado: (2017)

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial
por: Carrera, Fernando, et al.
Publicado: (2010)

Acute onset anterior uveitis after darbepoetin alfa infusion
por: Li, Jonathan, et al.
Publicado: (2015)

Darbepoetin Alpha Reduces Oxidative Stress and Chronic Inflammation in Atherosclerotic Lesions of Apo E Deficient Mice in Experimental Renal Failure
por: Arend, Nicole, et al.
Publicado: (2014)

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)
por: McMurray, John J.V., et al.
Publicado: (2013)

Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
por: Choi, Peter, et al.
Publicado: (2013)

Darbepoetin-α increases the blood volume flow in transplanted pancreatic islets in mice
por: Menger, Maximilian M., et al.
Publicado: (2020)

A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia
por: Ludwig, Heinz, et al.
Publicado: (2014)

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
por: Kruit, W. H., et al.
Publicado: (1996)

A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A “Half-and-Half” Combination Therapy()
por: Shimamatsu, Kazumasa, et al.
Publicado: (2013)

A pharmacist‐managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial
por: van den Oever, Francisca Johanna, et al.
Publicado: (2020)

Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin
por: Sepah, Yasir J., et al.
Publicado: (2022)

Correction to: Darbepoetin-α increases the blood volume flow in transplanted pancreatic islets in mice
por: Menger, Maximilian M., et al.
Publicado: (2021)

“Anæmia,” Physician’s Dose Book
Publicado: (1887)

Transfusion-dependent anaemia treatment using continuous erythropoietin receptor activator (epoetin β pegol) and roxadustat after darbepoetin treatment failure in low-risk myelodysplastic syndrome: a case report
por: Ikenoue, Tatsuyoshi, et al.
Publicado: (2021)

Antioxidant and antiapoptotic effects of darbepoetin-α against traumatic brain injury in rats
por: Kertmen, Hayri, et al.
Publicado: (2015)

A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS
por: Zafar, Aneeqa Ahsan, et al.
Publicado: (2020)

Iron status and erythropoiesis response to darbepoetin alfa in dogs with chronic kidney disease
por: BHAMARASUTA, Chayanont, et al.
Publicado: (2021)

Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study
por: Mafodda, Antonino, et al.
Publicado: (2017)

Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy
por: Hirsh, Vera, et al.
Publicado: (2007)

Oral iron supplementation and anaemia in children according to schedule, duration, dose and cosupplementation: a systematic review and meta-analysis of 129 randomised trials
por: Andersen, Christopher T, et al.
Publicado: (2023)

Dose Schedule Optimization and the Pharmacokinetic Driver of Neutropenia
por: Patel, Mayankbhai, et al.
Publicado: (2014)

Pretreatment with Darbepoetin Attenuates Renal Injury in a Rat Model of Cisplatin-Induced Nephrotoxicity
por: Choi, Dae Eun, et al.
Publicado: (2009)

Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study
por: Schaefer, Franz, et al.
Publicado: (2015)

Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents
por: Lee, Sung-Eun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hfnmtqj16j5mvg988h14ru8535